G(D2) oligosaccharide: Target for cytotoxic T-lymphocyte (CTL) (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


G(D2) oligosaccharide: Target for cytotoxic T-lymphocyte (CTL) (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 36:A2846 1995. Unique Identifier : AIDSLINE ICDB/96610619
Zhao X; Cheung NV; Dept. of Pediatrics, Memorial Sloan Kettering Cancer Center, New; York, NY 10021


Abstract: Carbohydrate antigens rarely provide target epitopes for CTL. Disialo-ganglioside G(D2) is expressed at high levels among human tumors (neuroblastomas, SCLC, melanomas, sarcomas, brain tumors) and a small group of murine lymphomas. Immunization of C57Bl/6 mice with irradiated EL4 cells stimulated a specific CTL response and protected these animals from engraftment of EL4 lymphoma. The CTL activity resided in the CD4- and CD8+ population, was dependent on TCR alpha beta and not removed by anti-NK immunoabsorption, but was restricted to GD2-oligosaccharide and H-2b bearing targets. CTL activity was completely inhibited by GD2-oligosaccharide specific monoclonal antibodies and their F(ab')2 fragments, but not by a large panel of IgG3 myelomas or antibodies against GD3 or GM2. Soluble GD2 did not inhibit specific tumor lysis. RMA-S lymphoma cells (GD2+, H-2b-, TAP2-deficient) were resistant to GD2-specific CTL. Sialic-acid-containing peptides eluted from EL4 lymphoma cells could (1) stabilize H-2 molecules on RMA-S cells, and (2) sensitize them for GD2-specific CTL. Control peptides (derived from VSV-NP and G(D2)-negative lymphomas) could also stabilize H-2 on RMA-S but were resistant to GD2-specific CTL. These H-2 binding peptides could be purified by anti-GD2 affinity chromatography. We postulate a new class of epitopes for T cells where branched-chain carbohydrate residues are linked to peptides that bind to the MHC class I pocket. While analogous to the hapten TNP, the potential implications of carbohydrates as antigenic epitopes for CTLs in biology are considerable.
Keywords: Animal CD4-Positive T-Lymphocytes/IMMUNOLOGY CD8-Positive T-Lymphocytes/IMMUNOLOGY G(M2) Ganglioside/*IMMUNOLOGY Gangliosides/*IMMUNOLOGY *Immunotherapy, Adoptive Lymphoma/*IMMUNOLOGY/*THERAPY Mice Oligosaccharides/*IMMUNOLOGY T-Lymphocytes, Cytotoxic/*IMMUNOLOGY ABSTRACTKWDanimalcd4-positivet-lymphocytes/immunologycd8-positivet-lymphocytes/immunologyg(m2)ganglioside/KWDimmunologygangliosides/KWDimmunologyKWDimmunotherapy,adoptivelymphoma/KWDimmunology/KWDtherapymiceoligosaccharides/KWDimmunologyt-lymphocytes,cytotoxic/KWDimmunologyabstract
960430
M9640027

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .